Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E. Gordon AN, et al. Among authors: edwards rp. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):785-92. doi: 10.1111/j.1525-1438.2005.00137.x. Int J Gynecol Cancer. 2005. PMID: 16174225 Free article. Clinical Trial.
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG. Vergote I, et al. Among authors: edwards rp. Int J Gynecol Cancer. 2010 Jul;20(5):772-80. doi: 10.1111/igc.0b013e3181daaf59. Int J Gynecol Cancer. 2010. PMID: 20973267 Clinical Trial.
Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
Ricciuti J, Liu Q, Khan ANMNH, Joseph JM, Veuskens B, Giridharan T, Suzuki S, Emmons T, Yaffe M, Kuijpers TW, Jongerius I, Brouwer M, Pouw RB, Odunsi K, Frederick P, Mager KL, Lele S, Gaulin N, Hakim C, Edwards RP, Olawaiye AB, Sukamanovich P, Taylor S, Elishaev E, Zsiros E, Modugno F, Moysich K, Segal B. Ricciuti J, et al. Among authors: edwards rp. Gynecol Oncol. 2025 Jan 6;193:49-57. doi: 10.1016/j.ygyno.2024.12.006. Online ahead of print. Gynecol Oncol. 2025. PMID: 39764857
Association of neighborhood social vulnerability with ovarian cancer survival.
Borho L, Elishaev E, Bao R, O'Brien E, Dinkins K, Berger J, Boisen M, Comerci J, Courtney-Brooks M, Edwards RP, Garrett AA, Kelley JL, Lesnock J, Mahdi HS, Olawaiye A, Rush S, Sukumvanich P, Taylor S, Aneja R, Norian L, Arend RC, Modugno F. Borho L, et al. Among authors: edwards rp. Gynecol Oncol. 2024 Nov 21;192:32-39. doi: 10.1016/j.ygyno.2024.10.030. Online ahead of print. Gynecol Oncol. 2024. PMID: 39577071 Free article.
Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1.
Taylor JL, Kokolus KM, Basse PH, Filderman JN, Cosgrove CE, Watkins SC, Gambotto A, Lowe DB, Edwards RP, Kalinski P, Storkus WJ. Taylor JL, et al. Among authors: edwards rp. Vaccines (Basel). 2024 Jul 15;12(7):777. doi: 10.3390/vaccines12070777. Vaccines (Basel). 2024. PMID: 39066414 Free PMC article.
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs.
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura CM, Sander C, Withers H, Long MD, Chavel C, Olejniczak SH, Minderman H, Kirkwood JM, Edwards RP, Storkus WJ, Romero P, Kalinski P. Dong B, et al. Among authors: edwards rp. Cancer Immunol Res. 2024 Oct 1;12(10):1421-1437. doi: 10.1158/2326-6066.CIR-24-0061. Cancer Immunol Res. 2024. PMID: 38949179
291 results